Company News: J&J nixes production of heart stent, Sanofi pairs with Audion

Share this article:

Johnson & Johnson company Cordis has announced that it will discontinue the development of the Nevo Sirolimus-Eluting Coronary Stent in order to focus on other cardiovascular therapies that are more in patient demand. Cordis will also halt production of Cypher and Cypher Select Plus Sirolimus-Eluting Coronary Stents by the end of 2011, according to a release.

Recently rebranded big pharma Sanofi has announced a two-year research partnership with biopharma company Audion Therapeutics with the objective of developing potential treatments for hearing loss. The collaboration will utilize technology developed at the Massachusetts Eye and Ear Infirmary – one of the world's leading research facilities devoted to the study of hearing and deafness – for the optimization of small molecules by using a regenerative medicine approach.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Avastin pockets another Priority Review label

It's the second for this cancer drug in two weeks.

Court invalidates some healthcare subsidies

The lawsuit has been wending its way through the courts for a while, and, although it is being deliberated in several other venues, the decision is part of a legal dispute that puts patients in the 36 states offering federal exchanges in limbo.

FDA generic division overhaul kicks in

The Food and Drug Administration has been intent on elevating and reorganizing its office of Generic Drugs since 2012.